Appeal Takes Place Against NICE Osteoporosis Decision Which Restricts Access To Effective Medicines And Puts Patients At Unnecessary Risk Of Fracture

An appeal hearing involving the National Osteoporosis Society (NOS), the Alliance for Better Bone Health and Servier Laboratories Ltd takes place after the National Institute for Health and Clinical Excellence (NICE) recommended only one single treatment (alendronate) for the estimated 2 million1 post-menopausal osteoporosis sufferers in England and Wales. Unfortunately, this treatment is not appropriate for all women with osteoporosis. [click link for full article]

More: continued here

Filed under: Bones on October 25th, 2007